Evaluation of the immune-profiling for patients participating in Phase Ib/II Study of BBI608 in Combination with Pembrolizumab and the relationship between the immune-profiling and efficacy using paired biopsies and peripheral blood.

Evaluation of the immune-profiling for patients participating in Phase Ib/II Study of BBI608 in Combination with Pembrolizumab and the relationship between the immune-profiling and efficacy using paired biopsies and peripheral blood. - SCOOP BM study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024500

Enrollment

Registered

2016-10-20

Start date

2016-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Participate in SCOOP study 2)Patients who can provide written informed consent

Exclusion criteria

Exclusion criteria: 1)Patients who are unfit for the study as determined by the attending physician

Design outcomes

Primary

Measure	Time frame
Evaluation of the immune-profiling.	—

Countries

Japan

Contacts

Public ContactYasutoshi Kuboki/Akihito Kawazoe

National Cancer Center Hospital East Department of Experimental Therapeutics and GI Oncology

scoop_core@east.ncc.go.jp04-7133-1111

Outcome results